MediciNova says SEANOBI-ALS expanded-access study of MN-166 reaches 200-patient enrollment target
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) | MNOV Stock News
<![CDATA[Modern Communication Between FDA, Biotech, and Investors: Q&A with David Crean]]>